

EU MARKET DEVELOPMENT INITIATED FOR APAS® PHARMAQC

Alongside a presentation from AstraZeneca at the PharmaLab-Congress

Adelaide, Australia, 23 November 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in microbiology automation using artificial intelligence, is pleased to announce that the Company has launched the marketing of the APAS® PharmaQC technology in Europe, at the annual PharmaLab-Congress and Exhibition (**PharmaLab**) held in Dusseldorf, Germany (20-22 November 2023). During the conference, AstraZeneca presented to delegates on their experience using APAS® PharmaQC and their vision for the implementation of the technology within their routine environmental monitoring process.

Key Points:

- **APAS® PharmaQC exhibited on Clever Culture Systems booth with virtual demonstration for delegates**
- **AstraZeneca oral presentation on implementation of APAS® PharmaQC for environmental monitoring**
- **PharmaLab 2023: Annual conference presenting the latest developments for pharmaceutical laboratories**
- **Attended by key decision makers within pharmaceutical quality control and microbiology departments**

Commercial activation of APAS® PharmaQC in Europe

The Company commenced marketing activities of the APAS® technology for environmental monitoring in Europe. This builds on the US marketing launch at the Parental Drug Association Pharmaceutical Microbiology Conference in Washington DC in October 2023. Building awareness of APAS® PharmaQC within the new pharmaceutical microbiology segment is important to establish the brand and technology for potential pharmaceutical customers that perform manual routine Environmental Monitoring practices. The initial positive performance data generated by both the Company and AstraZeneca lays solid foundations ahead of finalising this product development in the first quarter of the 2024 calendar year.

AstraZeneca Presentation at the Conference

The conference included presentations from industry commentators on the key challenges and solutions facing pharmaceutical laboratories. As part of the programme for “*Alternative and Rapid Microbiological Methods*”, **AstraZeneca’s Andrew Gravett** provided an oral presentation on **Automated Environmental Monitoring Plate Reading Powered by AI**, discussing benefits and considerations of implementing APAS® PharmaQC within their environmental monitoring process. The presentation outlines their envisaged future state using APAS® PharmaQC for the routine screening of environmental monitoring samples within their workflow.

The AstraZeneca presentation can be read in full on the LBT website: <https://www.lbtinnovations.com/automated-reading-of-agar-plates-using-ai/>

LBT CEO and Managing Director, Mr Brent Barnes said:

“PharmaLab has been our first demonstration of APAS® PharmaQC to a European audience. Improving data integrity for environmental plate reading is a key interest area for regulators currently and our APAS® solution offers a unique value proposition with end-to-end digital traceability coupled with important high-throughput automation providing efficiency to laboratories.

The presentation by AstraZeneca provides an important users-perspective on the benefits APAS® PharmaQC can have for customers looking to implement a best practice environmental monitoring process.

The conference provided an ideal environment to engage with key pharmaceutical decision makers and allowed me to conduct important site visits with potential pharmaceutical customers in the region.”

PharmaLab Congress (Dusseldorf, Germany; 20-22 November 2023)



Clever Culture Systems team with Andrew Gravett, AstraZeneca at PharmaLab-Congress 2023

The annual PharmaLab Congress is the leading European conference for pharmaceutical laboratory and quality control professionals, presenting the latest developments in laboratory methods, systems, and regulations for pharmaceutical manufacturers.

During the conference, the Company presented APAS® PharmaQC on the Clever Culture Systems booth, including a virtual demonstration of the technology available for delegates. This provided an opportunity to network and engage with delegates whilst providing an interactive experience to understand how APAS® PharmaQC could benefit their environmental monitoring processes.

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com